China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG: 1558) announced receiving marketing approval from the National Medical Products Administration (NMPA) for its Category 1 drug yiqibuvir. The non-structural protein 5B (NS5B) inhibitor is approved for use in combination with netanasvir in adult chronic hepatitis C virus (HCV) infections of genotypes 1, 2, 3, and 6, including patients previously treated with interferon, with or without compensatory cirrhosis.
Approval and Indication
The approval marks a significant step in treating chronic HCV infections in China. Yiqibuvir is designed to target the NS5B protein of the virus, offering a new therapeutic option for patients who have not responded adequately to previous treatments.
Related Drug Approval
In February this year, HEC’s non-structural protein 5A (NS5A) inhibitor, antaitasvir, was also approved in China for the same indication. This further strengthens YiChang HEC’s portfolio in HCV treatment.-Fineline Info & Tech
Leave a Reply